Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
FREDERICK, Md., Jan. 04, 2018 -- BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com makes wearable, drug-free chronic pain therapy medical devices. It is pleased to announce that the UK’s government funded public health service, National Health System (NHS), has approved our application to cover and pay for ActiPatch® Musculoskeletal Pain Therapy. The NHS estimates that almost half of the 50 million UK adults may be living with chronic-pain¹, which is why there are more than 100,000 physician visits every day for musculoskeletal pain alone².
The ActiPatch is a drug-free, wearable medical device that regulates peripheral nerve activity to provide pain relief. The NHS based its decision considering strong clinical evidence and a health economics study, which found that ActiPatch significantly decreased pain and improved quality of life, while reducing overall healthcare costs by 42% (58.5% reduction in physician appointment costs, 35% reduction in prescription medication costs).
“This is a major win for pain sufferers in the UK, since they will now be able to obtain a prescription for ActiPatch, the cost of which will be covered by the government,” stated Ian Rawe, Ph.D., Director of Clinical Research at BioElectronics. “We commend this move by the NHS, as this will open up the doors for reimbursement in the US and other managed care markets. This will likely have a tremendous impact on our sales and marketability of the product in the UK and elsewhere,” said Keith Nalepka, VP of Sales & Marketing at BioElectronics.
With the addition of ActiPatch to list of approved treatments, chronic pain sufferers now have access to paid safe, drug-free chronic pain relief. The ActiPatch will be listed for payment coverage in April.
About BioElectronics Corporation
BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: For more information, please visit www.bielcorp.com.
References
1 NHS, "NHS Choices," January 2018. [Online]. Available: https://www.nhs.uk/news/medical-practice/almost-half-of-all-uk-adults-may-be-living-with-chronic-pai....
2 Arthritis Research UK, "Muscloskeletal Matters," Keele University, 2009.
Contact: Paul Knopick 940.262.3584 [email protected]
